Health Claims Law Includes Effect On Existing Disease – Saw Palmetto Appeal
This article was originally published in The Tan Sheet
Executive Summary
A Washington, D.C. federal court committed a "plain and reversible error" when it upheld FDA's decision to deny a health claim linking saw palmetto extract to the treatment of benign prostatic hyperplasia symptoms, according to an appellate brief filed May 16
You may also be interested in...
Saw Palmetto Claims Case Set For November Oral Arguments
FDA argues it never violated First Amendment rights of plaintiffs Julian Whitaker et al. when it denied saw palmetto health claims because they were never considered under the health claim provisions of the Dietary Supplement Health & Education Act
Saw Palmetto Claims Case Set For November Oral Arguments
FDA argues it never violated First Amendment rights of plaintiffs Julian Whitaker et al. when it denied saw palmetto health claims because they were never considered under the health claim provisions of the Dietary Supplement Health & Education Act
Saw Palmetto Claims Case Set For November Oral Arguments
FDA argues it never violated First Amendment rights of plaintiffs Julian Whitaker et al. when it denied saw palmetto health claims because they were never considered under the health claim provisions of the Dietary Supplement Health & Education Act